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Conclusions
Quantitative assessment of albumin concentration in 
serum, ascitic fluid and lymph is not an index revealing the 
prognosis in terms of evolution of ascites to patients with 
cirrhogenous decompensated cirrhosis.  This study found 
that serum-ascites albumin gradient does not reveal a signi-
ficant difference in the case of resistant and refractory ascites. 
Ascites albumin gradient decreases during the evolution of 
lymph and ascitic syndrome and has a tendency to decrease 
with the progression of advanced forms of ascitic syndrome. 
Implementation of the notion of serum-ascites-lymph albu-
min gradient and its significance as a criterion of evolution 
for ascitic syndrome requires further study and validation.
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Abstract
This research presents the experience of the Arterial Hypertension Department in the treatment of patients with essential hypertension and 
microalbuminuria.  The study focused on the analysis of clinical observation materials according to the protocol, established in a group of 100 patients, of 
whom 50 were treated with angiotensin II converting enzyme inhibitors Ramipril and 50 were treated with angiotensin II receptor antagonist Eprosartane. 
Both drugs have proven beneficial effect on renal function parameters, especially in microalbuminuria at all stages of control with a peak at the end of 
the follow-up period.  However, the treatment with AT1-receptor antagonist Eprosartan has proven to be superior to angiotensin II in converting enzyme 
inhibitor Ramipril.
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Introduction
Arterial hypertension contributes to prognostic worsening 
depending on the level of subclinical organ damage and on 
the associated cardiovascular risk factors.
The most recent guideline on hypertension management, 
elaborated by the European Society of Hypertension in 2009, 
suggests that “based on recent trial evidence it is recommen-
ded to aggressively lower systolic and diastolic blood pressure 
to values of at least 140/90 mm Hg and lower if tolerated in 
all patients, and to values less than 130/80 mm Hg in diabetic 
patients considering the fact that frequently, especially in the 
elderly it could be difficult to reach values of systolic BP lower 
than 140 mm Hg” [1].
In general, lowering blood pressure treatment reduces 
the risk of stroke by 35-40%, for acute myocardial infarction 
(AMI) by 20-25%, chronic heart failure by 50% and chronic 
renal failure by 16-26% [2].
Arterial hypertension continues to be a serious issue in 
modern medicine and clinical trials have proven that through 
good control of BP values, the rate of cardiovascular events 
can be significantly reduced.  The National Programs for de-
tection and treatment of arterial hypertension have effectively 
led to the lowering of BP values, in the same time reducing 
the cardiovascular risk [3].
Chronic renal disease is a frequent complication of arterial 
hypertension and it favors the elevation of BP values through 
mechanisms due to renal dysfunction.  Arterial hypertension 
associated with renal dysfunction usually presents great di-
fficulties in treatment.
Kidney damage, even minor (microalbuminuria), has 
been confirmed as a major negative predictive factor in many 
diseases.  In the mid ’80s the first observations were made 
which associated increased urinary albumine excretion with 
amplification of cardiovascular morbidity and mortality, both 
in diabetic patients and hypertensive ones.
Since the first findings, microalbuminuria (MA) was 
frequently evaluated in big cardiovascular epidemiological 
trials, becoming also an essential parameter in modern cli-
nical evaluation.
Microalbuminuria in patients with essential arterial 
hypertension represents a serious problem, associated either 
with the alteration of vascular hemodynamics or glomerular 
selectivity, or with the process of initial nephroangiosclerosis 
or activation of the sympatic nervous system.
Влияние рамиприла и эпросартана на функциональное состояние почек у пациентов 
с гипертонической болезнью и микроальбуминурией при длительном лечении
В статье излагается собственный опыт лечения 100 пациентов с эссенциальной гипертонией и микроальбуминурией на протяжении 12 
месяцев.  В I-й группе (50 пациентов) принимали ингибитор ангиотензин-превращающего фермента Рамиприл.  Во II-й группе (50 пациентов) 
принимали блокатор рецепторов ангиотензина II Эпросартан.  Результаты исследования свидетельствуют о нефропротективной эффективности 
не только хорошо знакомого ингибитора ангиотензин-превращающего фермента Рамиприла, но и нового блокатора рецепторов ангиотензина 
II Эпросартан.
Ключевые слова: гипертоническая болезнь, микроальбуминурия, ингибитор ангиотензин-превращающего фермента, блокатор рецепторов 
ангиотензина II.
Different authors report a microalbuminuria prevalence 
of 5-10% in the general population, 4.1-40% in patients with 
essential arterial hypertension and 16-40% in patients with 
diabetes mellitus.  Generally, the presence of MA depends 
on age, race, body weight and values of blood pressure.  It 
is detected more frequently in black individuals – 14.3%; in 
those aged < 60 years 6.2%; smokers -1.4%; hypertensive - 
35%; obese – 3.6% [4].
Microalbuminuria represents a urinary albumine excreti-
on of 30-300 mg/24 hours or nocturne of 20-200 μg/min. The 
diagnosis of renal damage induced by arterial hypertension is 
based on the proof of reduced renal function and /or on the 
detection of increased urinary albumine excretion.
In the mid ’80s, the first trials showed a close relationship 
between increased urinary albumine excretion, cardiovascular 
morbidity and mortality both in diabetic and hypertensive 
patients.
Therefore, considering the importance of the problem, 
limited data in the specialty literature that would reflect 
the renal protection effects of a new angiotensin II receptor 
antagonist – Eprosartane, we have proposed the initiation of 
a prospective, randomized trial which would compare this 
drug to a well-studied angiotensin II - converting enzyme 
inhibitor – Ramipril.
The aim of the study
The evaluation of the action of long-term antihypertensive 
medication of angiotensin II – converting enzyme inhibitor 
Ramipril versus angiotensin II receptor antagonist Eprosar-
tane on the renal function and microalbuminuria.
Material and methods
One hundred subjects were included in the trial (48 men, 
52 women), mean age 51.1 ± 0.86 years with essential arterial 
hypertension of II-III grade and microalbuminuria, without 
associated clinical conditions.  After registration and the 
primary visit the patients signed an informed consent form 
in order to participate in the trial.  All antihypertensive drugs 
administered before have been suspended for a three week 
period.  After the end of this period the patients came for the 
second visit to measure BP and to confirm the presence of BP 
values ≥ 160/90 mm Hg.
According to the study protocol the patients were divided 
randomly in two groups:
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I group (50 patients) administered angiotensin II - con-
verting enzyme inhibitor – Ramipril in the mean dose (15.3 
± 1.2 mg/day) + indapamide 2.5 mg/day.
II group (50 patients) administered angiotensin II receptor 
antagonist – Eprosartane in the mean dose (850 ± 12.4 mg/
day) + indapamide 2.5 mg/day.
The renal excretory function has been evaluated through 
plasmatic urea, serum creatinine, glomerular filtration rate 
and microalbuminuria.
The patients were examined and treated in the clinic of 
Institute of Cardiology during 2007-2010.  The observation 
period lasted 12 months with evaluations in dynamics at 3, 
6, 9 and 12 months.
Results
The determination of renal excretory function is essential 
for the diagnosis of renal failure.  Also, exact knowledge of 
renal excretory capacity is indispensable for the determination 
of doses of drugs, in order to avoid potential accidents related 
to overdoses.
In initial stage the groups were comparable. In this way, 
serum urea varied in the range 2.7 - 19 mmol/l (mean 7.0 ± 
0.45 mmol/l) in group I and 3.8 – 14.9 mmol/l (mean 5.8 ± 
0.29 mmol/l) in group II, plasmatic creatinine varied in the 
range 50.1 – 296.7 mmol/l (mean 98.3 ± 5.34 mmol/l) in 
group I and, respectively, 50.1-271.4 mmol/l (mean 88.5 ± 
4.11 mmol/l) in group II.
The glomerular filtration rate was in the range 67.3 – 115.3 
ml/min (mean 87.2 ± 4.17ml/min) in group I and, respectively, 
69.3 – 111.3 ml/min (mean 94.5 ± 3.34ml/min) in group II 
(p < 0.05).
Table 1
Parameters of renal  function in the initial stage, (M ± m)
Groups PU (mmol/l)
SC 
(mmol/l)
GFR  
(ml/min)
MA  
(µg/min) p
I - Ramipril 7.0±0.45 98.3±5.34 87.2±4.17 73.1±5.52 < 0.05
II - Eprosartane 6.8±0.29 88.5±4.11 94.5±3.39 68.1±4.16 < 0.05
Abbreviations: PU – plasmatic urea; SC – serum creatinine; 
GFR – glomerular filtration rate; MA – microalbuminuria.
The microalbuminuria grade, which shows the presence 
of significant endothelial dysfunction, was also comparable 
in initial stage in both groups: in the range 35.7 – 98.6 µg/
min (mean 73.1 ± 5.52 µg/min) in group I and, respectively, 
40.3 – 93.1 µg/min (mean 68.1 ± 4.16 µg/min in group II p 
< 0.05) (tab. 1).
After 3 months of medication, plasmatic urea (mmol/l) 
was reduced by 11.4% (from 7.0 ± 0.45 to 6.2 ± 0.41) (p > 0.05) 
in group I and 20.5% (from 6.8 ± 0.29 to 5.4.± 0.18) (p < 0.05) 
in group II; after 6 months in group I by 14.2% ( from 7.0 ± 
0.45 to 6.0 ± 0.27) (p < 0.05) versus 19.1% (from 6.8 ± 0.29 
to 5.5 ± 0.16) (p < 0.05) in group II; after 9 months by 21.4% 
(from 7.0 ± 0.45 to 5.5 ± 0.2) (p > 0.05) in group I and 23.5% 
(from 6.8 ± 0.29 to 5.2 ± 2.2) (p > 0.05) in group II and after 
12 months of observation by 15.7% (p < 0.05) and 26.4% (p 
< 0.05) respectively (fig. 1).
Serum creatinine (mmol/l) after 3 months of medication 
reduced nonsignificantly by 2% (from 98.3 ± 5.3 to 96.3 ± 
6.5) in patients receiving Ramipril and statisticaly authentic 
– by 15.1% (from 96.5 ± 4.1 to 81.9 ± 2.2) (p < 0.05) using 
Eprosartane.
This trend became statistically authentic from 6 months 
of medication on, but more evident with the administration 
of Eprosartane, the peak being reached to the end of 12 
months of medication – 9.5% group I versus 18.5% group II, 
respectively (fig. 2).
The glomerular filtration rate decreased nonsignificantly 
in both therapeutic schemes after 3 months of medication – 
about 2%.  This became statistically authentic from 6 months 
of medication on, but more evident with the administration of 
Eprosartane, the peak being reached at the end of 12 months 
of medication – 31.4% group I versus 22.1% group II.  The 
reduction of renal flow is a normal connotation of systemic 
blood pressure, however, the absolute values of glomerular fil-
tration rate didn’t pass above normal after medication (fig. 3).
The values of microalbuminuria had an impressive 
evolution.  The 3 month-long treatment with Ramipril or 
Eprosartane resulted in a comparable reduction, statistically 
authentic, of microalbuminuria – by 67% and 65% (p < 0.05), 
respectively.  This was revealed at 6, 9 and 12 months of ob-
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Fig. 1.  The evolution of plasmatic urea parameters 
depending on medication.
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Fig. 2.  The evolution of serum creatinine parameters 
depending on medication.
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servation.  At the end of the observation period the values 
of microalbuminuria reached normality (< 20µg/min) in all 
subjects treated with Eprosartane, having average values of 
7.4±1.2 which represents a difference of 89.4% compared to 
initial (p < 0.001) (fig. 4).
Ramipril has also been efficient, but a little more modestly, 
the average reduction compared to initial being of 87.5% (from 
73.1 ± 5.5 µg/min to 9.1 ± 1.4 µg/min).  Concomitantly in 5 
patients from group I the values of MA passed nonsignificantly 
the normal target value.
Generally, the presence of proteinuria in the daytime at 
initial stage was detected in 43 (86%) patients from group 
I and 40 (80%) from group II.  Long-term treatment with 
Ramipril or Eprosartane resulted in an important reduction 
of the number of patients with proteinuria.
Therefore, after 3 months of treatment the number of 
these patients decreased more than 2-fold in both groups, and 
after 6 months 4.3-fold at Ramipril administration and “sic” 
8-fold using Eprosartane. To the end of the trial the percent 
of patients with proteinuria reduced from 43% to 4% in the 
group treated with Ramipril and from 40% to 2% in those 
treated with Eprosartane (tab. 2).
Table 2
The prevalence of patients with proteinuria (Nr; %)
Group Initial 3  months
6  
months
9  
months
12  
months
I group  
(Ramipril) 43 (86%) 19 (38%) 10 (20%) 4 (8%) 2 (4%)
II group  
(Eprosartane) 40 (80%) 18 (36%) 5 (10%) 3 (6%) 1 (2%)
Recapitulating, the administration of angiotensin II - 
converting enzyme inhibitor Ramipril, as well of angiotensin 
II receptor antagonist Eprosartane did not have a negative 
impact on renal function.  It can be mentioned even a reduc-
tion of blood nitrogen evaluated through ureea and serum 
creatinine, despite of the reduction of glomerular filtration. 
The decrease, while nonsignificant of the renal flow, can be 
explained by efficient reduction of systolic blood pressure.
The greatest connotation is due to the normalization in all 
patients of the values of microalbuminuria at the administra-
tion of Eprosartane and reduction to normality in 90% of the 
ones treated with Ramipril.
Discussion
Almost 50 years have passed since arterial hypertension 
has been defined as cardiovascular risk factor for the systolic 
and diastolic values.  The rate of cardiovascular events raises 
concomitantly with systolic BP at any age, but the correlation 
of diastolic BP and cardiovascular mortality is directly pro-
portional only until the age of 50, and inversely proportional 
after the age of 60 [5].
Numerous randomized placebo-controlled trials have in-
vestigated the benefit of the lowering of blood pressure using 
different groups of antihypertensive drugs.
A similar approach was used in order to study new ARB 
II drugs. In SCOPE trial, in elderly patients (of more than 70 
years), candesartane which was often associated with a diu-
retic, reduced BP versus placebo with 3.2/1.6 mm Hg, noting 
a significant reduction of the non-fatal stroke incidence. In 
RENAAL and IDNT trials in hypertensive patients with dia-
betes mellitus and diabetic nephropathy, the adding of ARB 
II losartane or irbesartane led to a significant reduction of 
cardiovascular morbidity [6, 7].
In MOSES trial (hypertensive patients with supported 
anterior cerebrovascular event) a comparison was performed 
between medications with eprosartane vs calcium blocker ni-
trendipine.  During 2.5 years of observation, significantly less 
strokes (31%) were noted in patients treated with eprosartane 
in conditions of a similar decrease in BP values [8].
Present data confirm the impact of proteinuria, which is 
a marker of endothelial dysfunction, on general and cardio-
vascular morbidity.
In this way, Culleton and al. have examined the elderly 
population included in Framingham trial in the perspective 
of analysis of the association between proteinuria and the in-
cidence of coronary artery disease, cardiovascular and general 
mortality.  According to the data on other cardiovascular risk 
Fig. 3.  The evolution of glomerular filtration rate 
parameters depending on medication.
Fig. 4.  The evolution of microalbuminuria parameters 
depending on medication.
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factors, including elevation of serum creatinine, after 17 years 
of clinical studies proteinuria represented a risk factor for 
general mortality among the male and female population, the 
death risk being ampified 1.3 to 2.6 fold because of increased 
urinary protein excretion [9].
The importance of proteinuria as a risk factor has been 
studied in another even greater trial MRFIT.  After 6 years of 
observation the presence of proteinuria has been significantly 
and independently associated with general, cardiovascular 
and coronary artery disease mortality, the risk raising with 
the level of proteinuria [10].
The importance of proteinuria in cardiovascular mor-
bidity and mortality is deducted indirectly in the HOPE 
trial.  Treatment with ramipril decreased the risk for acute 
myocardial infarction by 22%, for stroke by 33%, cardio-
vascular mortality by 37% and general mortality by 24%. 
The risk for occurrence of clinically manifest diabetic ne-
phropathy reduced by 24%.  These effects were independent 
from the antihypertensive effect of ramipril.  The authors 
concluded that ramipril has an important vascular and 
renal protective effect [11].
Normaly, a minimum quantity of proteins with a mean 
of 80 mg/day is being excreted with urine, 15% of which are 
albumines.  Therefore, proteinuria is defined as an urinary 
protein excretion of more than 0.3 g in urine in 24 hours.  In 
case of febrile disease, urinary infection or excessive effort, 
proteinuria may become periodicaly significant, without a 
particular long term importance.
The proteins in normal and pathological urine are gene-
rated from three major sources:
• plasmatic proteins filtrated physiologicaly or pathologi-
caly by glomerular capilars and that avoids reabsorbtion 
at the level of proximal renal tubes;
• proteins secreted physiologicaly by tubular cells (for 
example, Tamm-Horsfall protein) or lost in the tubular 
lumenum because of tubular damage;
• proteins secreted by cells or glands in inferior urinary 
tract or proteines resulted from inflamation of the 
urinary tract.
In our study the presence of mild proteinuria (< 1g/24h) 
in initial stage has been observed in 86% patients in the 
group treated with Ramipril and 80% with eprosartane.  The 
long-term medication resulted in important reduction of the 
number of patients with proteinuria.
Therefore, after 3 months of treatment the number of 
these patients diminished more than 2-fold in both groups, 
and after 6 months 4.3-fold during Ramipril administration 
and “sic” 8-fold using Eprosartane.  At the end of the trial, the 
percent of patients with proteinuria reduced from 43% to 4% 
in the group treated with Ramipril and from 40% to 2% in 
those treated with Eprosartane.  In this way, we can conclude 
that ARB II Eprosartane has a renoprotective effect through 
reduction of proteinuria.
It is known the fact that microalbuminuria represents 
a high cardiovascular and renal risk factor compared to 
subjects with “normal” urinary excretion (< 30 mg/24h).  In 
MONICA trial it was demonstrated that microalbuminuria 
in hypertension represents an important and independent 
cardiovascular risk factor.  The presence of microalbuminuria 
in these patients correlates with a greater prevalence and seve-
rity of left ventricular hypertrophy, hypertensive retinopathy, 
“non-dipping” hypertension and carotid arteriosclerosis [12].
In Groningen trial, a doubling of urinary albumine con-
centration was associated with an increase by 29% of cardio-
vascular mortality and by 12% of noncardiovascular mortality. 
There is evidence that microalbuminuria is a marker not only 
for endothelial dysfunction in glomerules, but also in the 
whole vascular system[13].
In those 100 patients with moderate-to-severe hyperten-
sion included in our trial, the presence of microalbuminuria 
was mandatory and it constituted: 73.1 ± 5.52 μg/min in the 
group treated with Ramipril and 68.1 ± 4.15 μg/min with 
Eprosartane (p < 0.05).  The mean values of glomerular fil-
tration rate were within normal limits 87.2 ± 4.17 ml/min in 
the group treated with Ramipril and 94.5 ± 3.34 ml/min in the 
group treated with Eprosartane (p < 0.05).  Therefore, in the 
case of our trial it can be also firmly said that the presence of 
microalbuminuria confirms the fact that there were patients 
included with important vascular damage.
On antihypertensive treatment Ramipril versus Epro-
sartane in our trial the values of microalbuminuria had an 
impressive evolution.  Only 3 months of medication resulted 
in a statisticaly significant reduction from initial microalbu-
minuria 67% on Ramipril and 65% on Eprosartane (p < 0.05). 
At the end of the observation period (12 months) the level 
of microalbuminuria reached the norm limit (< 20 μg/min) 
in all subjects treated with Eprosartane, forming a difference 
of 89.4% compared to the initial (p < 0.001).  Ramipril was a 
little more modest, the decrease of microalbuminuria being 
of 87.5% compared to the initial, concomitantly in 10% of 
patients the values MA passed nonsignificantly the normal 
target value.
Despite of the absence of survival benefits, these data 
prove the necesity of use of ACE II or ARB II in hypertensive 
patients with high risk and chronic renal disease.
Conclusions
1. Microalbuminuria represents an independent and 
important cardiovascular risk factor in general population, 
diabetic and hypertensive, being a marker of generalized 
vascular dysfunction.
2. The presence of proteinuria has to lead not only to de-
tailed kidney investigations for the detection of the etiology of 
renal damage, but also to cardiologic exploration, evaluation 
of cardiovascular risk, as well as aggressive treatment.
3. Serious renoprotective effect (important reduction of 
microalbuminuria) is installed in 6 months from initiation of 
medication with Ramipril or Eprosartane.  Continuation of 
medication induces progressive reduction of microalbuminu-
ria, superior efficiency being found at the administration of 
angiotensin II receptor antagonist Eprosartane.
4. The administration of angiotensin II receptor antagonist 
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Eprosartane, in the presence of contraindications for angio-
tensin II - converting enzyme inhibitor Ramipril, is absolutely 
opportune in the presence of hypertensive microalbuminuria.
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Abstract
This paper investigates the influence of the copper coordination compounds CMT-28, CMT-67 and of the bacterial remedy BioR on the cathepsin 
D activity in liver in experimental cirrhosis.  The activity of cathepsin D was also detected electron-histochemicaly in the liver during the regression 
of experimental hepatic cirrhosis.  The result suggests that the coordinative compound CMT-67 used in combination with the bacterial remedy BioR 
has a pronounced stimulating effect on the enzymatic hydrolysis of the extracellular matrix under the action of cathepsin D and contributes to a more 
efficient breakdown of the excessive fibrous tissue in liver.  It was determined that the active cathepsin D is localized intracellularly in the lysosomes of 
hepatocytes, macrophages, fibroblasts and endothelial cells, as well as extracellularly on the collagen fibrils near the parenchymal and mezenchymal cells. 
In addition to its participation in the intracellular proteolysis, cathepsin D is secreted by the hepatocytes and connective tissue cells to the extra-cellular 
space and participates in the extracellular breakdown of the fibrous tissue.
Key words: cathepsin D, liver cirrhosis, coordinative compounds of cuprum, bacterial remedy BioR.
Активность катепсина D при экспериментальном циррозе печени  
и при введении координационных соединений меди и препарата бактериального происхождения BioR
Было изучено влияние координационных соединений меди CMT-28, CMT-67 и препарата бактериального происхождения BioR на 
активность катепсина D в печени при экспериментальном циррозе.  Активность катепсина D была также выявлена электронно-гистохимически 
в печени при регрессии экспериментального цирроза.  Результаты свидетельствуют о том, что координационное соединение меди CMT-67, 
введенное в комбинации с препаратом бактериального происхождения BioR, имеет выраженное стимулирующее влияние на ферментативный 
гидролиз внеклеточного матрикса под влиянием катепсина D и способствует более эффективному распаду фиброзной ткани в печени. 
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